Caxton Associates LP Grows Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Caxton Associates LP grew its position in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 249.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,934 shares of the company's stock after purchasing an additional 28,502 shares during the period. Caxton Associates LP owned approximately 0.13% of Fulgent Genetics worth $738,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Fulgent Genetics by 113.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company's stock valued at $7,346,000 after acquiring an additional 179,477 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Fulgent Genetics by 803.2% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,957 shares of the company's stock valued at $2,326,000 after buying an additional 112,011 shares during the last quarter. Inlight Wealth Management LLC acquired a new position in shares of Fulgent Genetics in the 4th quarter valued at about $685,000. Intech Investment Management LLC boosted its stake in shares of Fulgent Genetics by 248.3% in the fourth quarter. Intech Investment Management LLC now owns 43,539 shares of the company's stock worth $804,000 after buying an additional 31,037 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in Fulgent Genetics during the fourth quarter valued at approximately $411,000. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Trading Up 5.3 %

NASDAQ:FLGT traded up $0.99 during trading hours on Friday, reaching $19.55. 369,014 shares of the company were exchanged, compared to its average volume of 270,920. The stock's 50-day moving average is $17.80 and its 200-day moving average is $18.06. Fulgent Genetics, Inc. has a twelve month low of $14.57 and a twelve month high of $25.11. The firm has a market cap of $603.43 million, a PE ratio of -3.54 and a beta of 1.00.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.22. Fulgent Genetics had a negative return on equity of 1.81% and a negative net margin of 59.39%. The company had revenue of $73.46 million during the quarter, compared to analyst estimates of $71.26 million. During the same period in the previous year, the business earned ($0.01) EPS. Fulgent Genetics's quarterly revenue was up 14.0% on a year-over-year basis. As a group, research analysts anticipate that Fulgent Genetics, Inc. will post -0.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a research note on Wednesday, March 5th. Raymond James reiterated an "outperform" rating and issued a $25.00 price objective (up previously from $24.00) on shares of Fulgent Genetics in a research report on Monday, May 5th. Finally, Piper Sandler restated a "neutral" rating and set a $23.00 target price (up from $16.00) on shares of Fulgent Genetics in a research report on Tuesday, May 6th.

Insider Transactions at Fulgent Genetics

In related news, CFO Paul Kim purchased 100,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the acquisition, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72. This trade represents a 40.28 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 33.11% of the company's stock.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.